ARYx slashes workforce after licensing talks break down
This article was originally published in Scrip
Executive Summary
ARYx Therapeutics has reduced its workforce to less than 20 employees after licensing talks with other companies concerning its oral antiarrythmic agent budiodarone (ATI-2042) fell through.